Related Experiment Video
Updated: Jan 29, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Sarcopenia in CKD: a roadmap from basic pathogenetic mechanisms to clinical trials.
Alberto Ortiz1, Maria Dolores Sanchez-Niño1
1IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid; Fundacion Renal Iñigo Alvarez de Toledo-IRSIN and REDINREN, Madrid, Spain.
Sarcopenia and frailty significantly increase risks for patients with chronic kidney disease (CKD) and those on renal replacement therapy. Research explores their causes and the effectiveness of exercise programs in managing these conditions.
Area of Science:
- Nephrology
- Geriatrics
- Exercise Physiology
Background:
- Sarcopenia and frailty are critical risk factors in chronic kidney disease (CKD) patients, impacting outcomes.
- Debate persists regarding the pathogenesis of these conditions and optimal therapeutic strategies.
- Exercise programs are being investigated for their impact on CKD patient outcomes.
Purpose of the Study:
- To review current understanding of sarcopenia and frailty in CKD.
- To explore pathogenesis and therapeutic approaches, including exercise interventions.
- To assess the impact of exercise programs on dialysis and non-dialysis CKD patients.
Main Methods:
- Review of recent manuscripts published in Clinical Kidney Journal.
- Analysis of clinical trials assessing exercise programs in CKD patients.
- Discussion of pathogenesis, monitoring, and implementation of therapeutic strategies.
Main Results:
- Several studies address sarcopenia in CKD, focusing on pathogenesis and new therapies.
- Exercise programs show potential benefits for both dialysis and non-dialysis CKD patients.
- Clinical trials are evaluating the effectiveness of various exercise interventions.
Conclusions:
- Sarcopenia and frailty are significant concerns in CKD management.
- Exercise interventions represent a promising therapeutic avenue.
- Further research is needed to optimize exercise protocols and confirm outcome benefits.
More Related Videos
05:16Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
14:45Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Trial and Error and Algorithm
Energy Basics
Basicity of Aliphatic Amines
To measure the basicity of amines, two conventions are generally used. The first defines Kb as the basicity constant for the deprotonation reaction of water by the amine, as presented in Figure 1. Conventionally, lower Kb indicates higher...